Barry - surf yourself over to billkirn's website (search billkirn on the web) and check out the AGPH technical analysis, particularly the oscillator (the lower graph) showing sinusoidal movement superimposed on a general rise. We're at the lower resistance level and near the moving average. I'm thinking this must be the buy point because I keep having to fight investment fears of it dropping lower, to the point where I want to take downside protective action! I nearly covered my Nov. 47s with sold Nov. 52.5s, but didn't get filled. Had I done so, I could have bought them back and pocketed some real money.
Oh well.
I agree. Bottom line, after all the exchange between Henry and John, is that Viracept still looks as potent as Crix, is clearly better tolerated, meaning better compliance, hence more likely real world positive outcomes, and may prove to be the PI of choice for the additional reason that it has less cross resistance with other PIs.
A caveat to earnings expectations can be read on the AOL Motley fool board - AGPH apparently used up their tax carryforwards, having acheived profitability earlier than expected, so earnings after taxes will be diminished, since they're paying 40% tax. (Anyone who knows this stuff better than I please clarify).
Two general questions to the board. Did AGPH move their earnings date up? If so, any thoughts about why? Second, any thoughts about the delay of NDA for Thymitaq, per the annual report? Since I don't know the strategy the company was using (i.e. possible early registration with only Phase II data, etc.), the mention of the 1 yr delay would seem to indicate that the best possible scenario didn't pan out when discussed with the FDA folks, but that they are still intent on taking the drug to market, albeit at a slower pace.
Regards,
Randy |
